Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack of sustainable innovation this article argues that, maybe, it is time for the pharmaceutical industry to… Read More
Automation Of Solid/Powder Dispensing: Much needed, but cautiously used! By Dr John Comley This article investigates solid/powder dispensing in pharma and biotech, examines where it is most used, whether there exists a need to apply automation and what is motivating its wider use today. It reveals how concerns over problematic… Read More
Recent Technology Advances Transforming Pharmaceutical Drug Discovery and Development By Dr Coiln Brenan, and Dr Bill LaMarr The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more interest than those… Read More
Early Validation: The difference between success and failure? By Mike Benevento and Victor Bornsztejn Validation is typically associated with drug production and manufacturing, and often considered not to impact drug discovery and development. In fact, this assumption is not true and despite the fact that early-stage research may not require… Read More
Restructuring Proteomics to Enable Personalised Cancer Care By Dr Henry Rodriguez The genomics community has made great strides in our understanding of the molecular basis of cancer and these advances are slowly beginning to change the way we diagnose and treat patients. But genomic studies alone cannot capture the complete… Read More
Generation II DNA Sequencing Technologies By Dr Stephen F. Kingsmore, Dr Jenny C. van Velkinburgh, Dr Joann Mudge, and Dr Gregory D. May Generation II DNA sequencing has been widely heralded as a disruptive technology, generating tens of millions of random short sequences at efficiencies up to 20,000-fold greater than… Read More
Predicting Transporter-mediated Drug-drug Interactions Based on in Vitro Cell Permeability Assays By Dr Chris Bode Drugs may fail in clinical development or post-marketing for a variety of reasons: they may simply not be as effective as anticipated; poor pharmacokinetic properties may prevent them from reaching their intended target in therapeutic… Read More
Building a Robust Portfolio of New Medicines to Combat Malaria By Dr Timothy N.C. Wells Malaria is one of the biggest killers of our time. Current estimates from the World Health Organisation (WHO) suggest that more than 250 million people are at risk worldwide. More significantly, almost a million people… Read More
Biomarker Signal Definition By Dr Gordon F. Kapke and Dr Nigel Brown Due to the numerous challenges in the industry, pharmaceutical companies are examining all aspects of the drug development process and rebuilding their associated business models as necessary. Companies need to improve success in late stage development, but what… Read More
The Potential of High-resolution Human Immune Cell Assays to Aid the Pre-clinical to Clinical Transition of Drug Development Projects By Dr Catherine A. Brady The effort to develop drugs that interact with the human immune system (whether by accident or design) has been dogged by a mismatch between the data… Read More
Outsourcing for Innovation Takes on New Meaning By Richard Boehner Large pharmaceutical companies are moving quickly to outsource their drug discovery operations, predominantly to lower costs. This article argues that if outsourcing is done to capture value, ie developing and preserving intellectual property as a key competitive differentiation as well… Read More
A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema By Dr Edward E. Berger Emphysema is a progressive, debilitating disease that affects approximately 4.1 million people in the United States or roughly 1% of the US population. The disease is characterised by destruction of lung tissue as a result of inflammation… Read More
Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics By Dr William E. Fogler Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical… Read More
High Throughput Screening in Academia - Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules… Read More
Next Generation Immunoassay Systems and the Revival of Protein Biomarkers By Dr John Todd and Dr Sara J. Agee Proteins are the machinery that drive most biological processes; however, measuring their concentrations at low levels has been historically impeded by a lack of appropriately sensitive technology. Advances in immunoassay technology,… Read More
Prediction versus Attrition in Drug Discovery & Development By Professor Malcolm Young The research-intensive part of the pharmaceutical industry is facing unusual commercial difficulties, whose elements are now well-known. A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium… Read More